Debiopharm Group™ is a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs. It in-licenses promising biologics and small molecule candidates.
The group develops its products with a view to licensing them out to pharmaceutical partners for sales and marketing.
Debiopharm Group is financially independent.
Debiopharm S.A.
A biopharmaceutical development company that in-licenses promising biologics and small molecule drug candidates for global development.
More info
Debio R.P.
Applied research, drug delivery systems, FDA and SwissMedic inspected production facility. More info
Debioinnovation S.A.
Financing of biotechnology and pharmaceutical start-ups to create synergies with Debiopharm Group. More info
Debiomanagement S.A.
The financial arm of Debiopharm Group. Debiomanagement comprises a Financial Department, a Real Estate Department and a Private Equity Department. More info
Debiopharm Group Strategic Committee
The Strategic Committee is a prospective think-tank advising the shareholders and the leadership of the group against the background of a changing environment. More info
Debiopharm Group Auditing Committee
The Auditing Committee monitors and enhances good administrative and management practices as well as risk control at group level. More info
